Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques.

To develop more potent JAK3 kinase inhibitors, a series of CP-690550 derivatives were investigated using combined molecular modeling techniques, such as 3D-QSAR, molecular docking and molecular dynamics (MD). The leave-one-out correlation (q2) and non-cross-validated correlation coefficient (r2) of the best CoMFA model are 0.715 and 0.992, respectively. The q2 and r2 values of the best CoMSIA model are 0.739 and 0.995, respectively. The steric, electrostatic, and hydrophobic fields played important roles in determining the inhibitory activity of CP-690550 derivatives. Some new JAK3 kinase inhibitors were designed. Some of them have better inhibitory activity than the most potent Tofacitinib (CP-690550). Molecular docking was used to identify some key amino acid residues at the active site of JAK3 protein. 10ns MD simulations were successfully performed to confirm the detailed binding mode and validate the rationality of docking results. The calculation of the binding free energies by MMPBSA method gives a good correlation with the predicted biological activity. To our knowledge, this is the first report on MD simulations and free energy calculations for this series of compounds. The combination results of this study will be valuable for the development of potent and novel JAK3 kinase inhibitors.

[1]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[2]  E. Toone,et al.  Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. , 2008, Chemistry & biology.

[3]  N. Santhi,et al.  Pharmacophore and Virtual Screening of JAK3 inhibitors , 2014, Bioinformation.

[4]  H. Kantarjian,et al.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.

[5]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[6]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[7]  G. Chan,et al.  Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. , 2009, The Journal of investigative dermatology.

[8]  G R Marshall,et al.  3D-QSAR: a current perspective. , 1995, Trends in pharmacological sciences.

[9]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[10]  T. Shows,et al.  tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. , 1990, Oncogene.

[11]  R. Jove,et al.  The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival , 2011, Leukemia.

[12]  W. Pitts,et al.  Chapter 12 Advances in the Discovery of Small Molecule JAK3 Inhibitors , 2009 .

[13]  Mladen Vinković,et al.  Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. , 2009, Journal of medicinal chemistry.

[14]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[15]  M. Hines,et al.  Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. , 2010, Journal of medicinal chemistry.

[16]  P. Roy,et al.  Exploring the impact of size of training sets for the development of predictive QSAR models , 2008 .

[17]  A. Wilks,et al.  Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase , 1991, Molecular and cellular biology.

[18]  S. Wold,et al.  Partial least squares analysis with cross‐validation for the two‐class problem: A Monte Carlo study , 1987 .

[19]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[20]  S. Nagamani,et al.  Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors. , 2011, Journal of molecular graphics & modelling.

[21]  Om Silakari,et al.  Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach , 2013, Molecular Diversity.

[22]  J. Gready,et al.  Combining docking and molecular dynamic simulations in drug design , 2006, Medicinal research reviews.

[23]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[24]  E. Liu,et al.  Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells , 1994, Nature.

[25]  V. Kyttaris.  Kinase inhibitors: a new class of antirheumatic drugs , 2012, Drug design, development and therapy.

[26]  C. Zerbini,et al.  Tofacitinib for the treatment of rheumatoid arthritis , 2012, Expert review of clinical immunology.

[27]  M. Bello.  Binding free energy calculations between bovine β‐lactoglobulin and four fatty acids using the MMGBSA method , 2014, Biopolymers.

[28]  Holger Gohlke,et al.  MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.

[29]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[30]  James R Kiefer,et al.  Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. , 2010, Journal of molecular biology.

[31]  D. Fox.  Kinase inhibition--a new approach to the treatment of rheumatoid arthritis. , 2012, The New England journal of medicine.

[32]  D. S. James,et al.  Naphthyl ketones: a new class of Janus kinase 3 inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[33]  G. Burmester,et al.  Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis. , 2013, Rheumatology.

[34]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[35]  Zhong-Chang Wang,et al.  Design, synthesis, biological evaluation and molecular docking of novel metronidazole derivatives as selective and potent JAK3 inhibitors , 2014 .

[36]  J. Johnston,et al.  Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2 , 1994, Nature.

[37]  J. O’Shea,et al.  Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.

[38]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[39]  F. Vincenti,et al.  Targeting JAK3 in kidney transplantation: current status and future options , 2011, Current opinion in organ transplantation.

[40]  Johann Gasteiger,et al.  Prediction of proton magnetic resonance shifts: The dependence on hydrogen charges obtained by iterative partial equalization of orbital electronegativity , 1981 .

[41]  A. Andres,et al.  JAK2, a third member of the JAK family of protein tyrosine kinases. , 1992, Oncogene.

[42]  T. Miller,et al.  AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B‐cell lymphomas , 2012, International journal of cancer.

[43]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[44]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[45]  M. Munchhof,et al.  The specificity of JAK3 kinase inhibitors. , 2008, Blood.

[46]  Ajay N. Jain.  Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[47]  J. Martini,et al.  SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[48]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.